Loading organizations...
Origin Capital is an investment firm whose principals deploy capital into early-stage unquoted businesses and smaller quoted companies. The firm primarily targets opportunities within the technology sector, including high-value manufacturing, life sciences, software, and IT infrastructure, while also engaging with financial services, consumer products, and media enterprises. They structure unquoted investment rounds typically ranging from £50,000 to £2 million, with pre-money valuations between £200,000 and £10 million.
The firm was established in 2007, founded by a collective of principals bringing extensive experience from business consultancy, accountancy, banking, and venture capital. This diverse background provided the foundational insight that early-stage enterprises benefit significantly from not just financial backing, but also deep operational and strategic guidance. This approach positions Origin Capital to leverage its team's hands-on expertise directly with its portfolio companies.
Origin Capital serves a portfolio of developing companies, particularly those in the nascent stages across various tech-centric industries. The firm's long-term vision centers on fostering the growth of these early-stage businesses by providing capital alongside strategic consultancy services. This integrated support aims to guide its investees through critical development phases, ensuring they can achieve their full potential in dynamic markets.
Key people at Origin Capital.
Origin Capital has 1 tracked investment across 1 company. The latest tracked deal is $25.0M Series A in ViaNautis in November 2023.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Nov 1, 2023 | ViaNautis | $25.0M Series A | 4BIO Capital, Lucy Edwardes Jones, Steven Biesmans | Parkwalk Advisors, Cystic Fibrosis Foundation, ELI Lilly And Company, Meltwind, O2H |
Key people at Origin Capital.